Shares of Steris Plc (NYSE:STE) have been given a consensus broker rating score of 1.25 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and three have given a strong buy rating to the company.
Brokerages have set a 1 year consensus price objective of $100.00 for the company and are expecting that the company will post $1.07 earnings per share for the current quarter, according to Zacks. Zacks has also given Steris Plc an industry rank of 161 out of 265 based on the ratings given to its competitors.
STE has been the topic of a number of research analyst reports. KeyCorp reissued an “overweight” rating and issued a $101.00 price target (up from $91.00) on shares of Steris Plc in a research note on Thursday, November 2nd. Zacks Investment Research lowered Steris Plc from a “buy” rating to a “sell” rating in a research note on Monday, November 6th. TD Securities raised their price target on Steris Plc from C$14.00 to C$16.00 and gave the stock a “buy” rating in a research note on Thursday. Raymond James Financial, Inc. raised their price target on Steris Plc from $90.00 to $95.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 9th. Finally, BidaskClub lowered Steris Plc from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st.
Steris Plc (NYSE STE) traded down C$1.30 on Monday, hitting C$86.85. The company had a trading volume of 235,400 shares, compared to its average volume of 475,037. The company has a current ratio of 2.80, a quick ratio of 2.18 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $7,386.80, a price-to-earnings ratio of 22.38 and a beta of 1.31. Steris Plc has a fifty-two week low of C$64.37 and a fifty-two week high of C$93.39.
Steris Plc (NYSE:STE) last issued its quarterly earnings results on Wednesday, November 1st. The company reported C$0.94 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of C$0.95 by C($0.01). Steris Plc had a return on equity of 11.49% and a net margin of 5.59%. The business had revenue of C$634.20 million during the quarter, compared to analyst estimates of C$629.02 million. During the same period in the previous year, the business posted $0.89 earnings per share. The firm’s quarterly revenue was down 1.9% on a year-over-year basis. research analysts forecast that Steris Plc will post 4.06 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 20th. Stockholders of record on Wednesday, November 22nd will be issued a $0.31 dividend. The ex-dividend date of this dividend is Tuesday, November 21st. This represents a $1.24 dividend on an annualized basis and a dividend yield of 1.43%. Steris Plc’s dividend payout ratio (DPR) is 73.81%.
In related news, insider Michael J. Tokich sold 11,000 shares of the firm’s stock in a transaction dated Monday, October 23rd. The stock was sold at an average price of C$92.00, for a total transaction of C$1,012,000.00. Following the sale, the insider now directly owns 58,588 shares in the company, valued at approximately C$5,390,096. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Karen L. Burton sold 3,270 shares of the firm’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of C$85.70, for a total value of C$280,239.00. Following the sale, the vice president now owns 11,807 shares in the company, valued at C$1,011,859.90. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 202,342 shares of company stock worth $17,729,692. Company insiders own 2.55% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Citigroup Inc. purchased a new stake in shares of Steris Plc during the 2nd quarter valued at about $206,000. Van Cleef Asset Management Inc purchased a new stake in shares of Steris Plc during the 2nd quarter valued at about $208,000. Cigna Investments Inc. New purchased a new stake in shares of Steris Plc during the 2nd quarter valued at about $209,000. BT Investment Management Ltd purchased a new stake in shares of Steris Plc during the 2nd quarter valued at about $210,000. Finally, Allegis Investment Advisors LLC purchased a new stake in shares of Steris Plc during the 2nd quarter valued at about $251,000. Institutional investors and hedge funds own 93.50% of the company’s stock.
WARNING: This piece of content was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/11/13/zacks-steris-plc-ste-given-100-00-average-target-price-by-analysts.html.
Steris Plc Company Profile
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Steris Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Plc and related companies with MarketBeat.com's FREE daily email newsletter.